Note: Ingredients listed on restricted chemical lists
EC/CAS
215-185-5/1310-73-2
Name of the chemical
sodium hydroxide
Concentration
<0.5 0.5%< >=5% <5% 0.5%<
EC/CAS
231-791-2/7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
limit (SCL
EC/CAS
201-766-0/87-69-4
Name of the chemical
L-(+)-tartaric acid
Concentration
N/A
General Information
Version
3
Revision date
2025-06-13
Product name
Oxaliplatin Injection (Solution for Intravenous Use) (Hospira Inc.)
Product name
Oxaliplatin Injection (Solution for Intravenous Use) (Hospira Inc.)
Identification on the label/Trade name
Not applicable Not determined
Chemical name
Not determined
1.2.1 Relevant identified uses
Pharmaceutical product used as Antineoplastic
Emergency telephone
1-800-424-9300, +1-703-527-3887
Icons in SDS
Company Information
company name
Hospira, A Pfizer Company
e-mail address of the competent person responsible for the Safety Data Sheet
pfizer-MSDS@pfizer.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H340, H360D
Hazard statements
Code
Statements
H340
May cause genetic defects
H360D
May damage the unborn child.
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Germ cell mutagenicity Category 1B - (H340) Reproductive toxicity Category 1B - (H360D) OSHA Classification Hazards not otherwise classified (HNOC) Not applicable Hazards classified under paragraph (d)(1)(ii) of 1910.1200 Not applicable
2.3 Other hazards
Not applicable (HNOC) An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).
Signal word
Danger
Hazard statements
H340 - May cause genetic defects H360D - May damage the unborn child
Precautionary statements
P321 - Specific treatment (see .? on this label) P201 - Obtain special instructions before use P280 - Wear protective gloves/protective clothing/eye protection/face protection P308 + P313 - IF exposed or concerned: Get medical advice/attention P202 - Do not handle until all safety precautions have been read and understood 2.5 % of the mixture consists of ingredient(s) of unknown acute oral toxicity. 2.5 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity. 2.5 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist). 2.5 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas). 2.5 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor). Unknown aquatic toxicity Contains 2.5 % of components with unknown hazards to the aquatic environment. Contains Oxaliplatin
PBT Substances
& vPvB The product does not contain any substance(s) classified as PBT or vPvB. Endocrine Disruptor Information This product does not contain any known or suspected endocrine disruptors. Note This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
